Skip to main content

What does a partner check before licensing or sourcing biotech material?

They check the development stage and the data supporting it, the intellectual property position, and whether manufacturing can scale. Biotech partnering is an evidence and rights question, so stage-appropriate disclosure matters more than breadth of claim.

A business development team is assessing whether a programme is real enough and protected enough to justify a partnering conversation.

Reviewed 4 August 2026

Plact Research

Scope and specifications

Technology platform and application
What the technology does and where it applies.
Development stage
Research, preclinical, clinical or commercial changes everything.
Intellectual property position
Patents granted, pending and their territories.
Manufacturing capability and scale
Whether the product can be made at commercial scale.
Regulatory pathway
The route and stage in each target market.
Quality systems in place
Determines readiness for regulated work.
Partnering model sought
Licensing, supply, co-development or acquisition.

Documents buyers may need

Documents buyers ask a biotechnology company for, what each proves, and whether it belongs on the public site
Intellectual property summaryAsked at: partnering discussion — the core assetPatent families, status and territoriesName it, share on request
Development stage data packageAsked at: due diligenceThe evidence supporting the current stageName it, share on request
Quality certificationAsked at: partner assessmentQuality systems appropriate to the development stagePublish it
Manufacturing capability statementAsked at: commercial assessmentScale achieved and scale achievableName it, share on request
Regulatory correspondence summaryAsked at: due diligenceInteractions and agreed pathway with authoritiesName it, share on request
Publication and peer review recordAsked at: credibility assessmentIndependently reviewed evidence for the platformPublish it
Material transfer and confidentiality termsAsked at: before any exchangeHow material and data are shared before a dealPublish it

Details for a useful enquiry

Technology and application of interest
Determines the fit.
Partnering model sought
Licensing, supply or co-development.
Development stage required
Partners have stage preferences.
Territory and rights of interest
Defines the deal shape.
Technical due diligence needs
What evidence will be required.
Timeline and decision process
Partnering timelines are long.

Questions suppliers ask

How much should a biotech company publish publicly?

Enough for a partner to determine fit and credibility: the platform, the application, the development stage, the publication record and the partnering model sought. The data package belongs behind confidentiality, but a site that says nothing specific cannot start a conversation either.

How should development stage be described?

Precisely and conservatively, using the standard terminology for the field. Partners assess risk by stage, and precision is read as competence. Ambiguity intended to make a programme look more advanced is detected quickly and remembered.

What role does the publication record play?

It is often the strongest public credibility signal available, because it is independently reviewed. Listing peer-reviewed publications lets a partner assess the science before contact, which is exactly what they want to do first.

Check which documents and standards your buyer needs; requirements vary by market, customer and contract.

Plact Research. Plact's editorial desk for buyer-evidence research. Industry standards, documents and buyer questions are researched and drafted with Plact's AI tools, then reviewed by Praveen Kavuri before publication. Every claim cites the standard, regulation or public source it rests on.

Related buyer questions

Put this to work on your website

See how Plact helps buyers find what you offer and send a useful enquiry.